Evidence map›Paper›PMID 37668277›Full record

ArticleInternational journal of methods in psychiatric research2023

An exploration of actigraphy in the context of ketamine and treatment-resistant depression.

Claire Punturieri, Wallace C Duncan, Dede Greenstein, Gavi Shandler, Carlos A Zarate, Jennifer W Evans

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of methods in psychiatric research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00088699 (Investigation of the Rapid), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00088699 phase1 / phase2completednot on this map

Investigation of the Rapid (Next Day) Antidepressant Effects of an NMDA Antagonist

TypeinterventionalSponsorNational Institute of Mental Health (NIMH)Ran2004 to 2017Enrolled67ConditionsDepression, Mood Disorders, Major DepresssionArmsKetamine, Placebo
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. An exploration of actigraphy in the context of ketamine and treatment-resistant depression.International journal of methods in psychiatric research · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 2 countries.

Claire PunturieriExperimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA.
Wallace C DuncanExperimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA.
Dede GreensteinExperimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA.
Gavi ShandlerExperimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA.
Carlos A ZarateExperimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA.
Jennifer W EvansExperimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA.ORCID https://orcid.org/0009-0002-7176-5759
National Institutes of Health · US

Funding

Glutamatergic Modulators for Rapid & Sustained Antidepressant EffectZIAMH002857 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI ZARATE, CARLOS · 2009 to 2025
$55.0M
Intramural NIH HHS ZIA MH002857NIH HHS NCT00088699NIMH NIH HHS ZIAMH002857
6 · The paper itself

Abstract

objectivesThis study explored the potential of non-parametric and complexity analysis metrics to detect changes in activity post-ketamine and their association with depressive symptomatology.

methodsIndividuals with treatment-resistant depression (TRD: n = 27, 16F, 35.9 ± 10.8 years) and healthy volunteers (HVs: n = 9, 4F, 36.4 ± 9.59 years) had their activity monitored during an inpatient, double-blind, crossover study where they received an infusion of ketamine or saline placebo. All participants were 18-65 years old, medication-free, and had a MADRS score ≥20. Non-parametric metrics averaged over each study day, metrics derived from complexity analysis, and traditionally calculated non-parametric metrics averaged over two weeks were calculated from the actigraphy time series. A separate analysis was conducted for a subsample (n = 17) to assess the utility of these metrics in a hospital setting.

resultsIn HVs, lower intradaily variability was observed within daily rest/activity patterns post-ketamine versus post-placebo (F = 5.16(1,15), p = 0.04). No other significant effects of drug or drug-by-time or correlations between depressive symptomatology and activity were detected.

conclusionsWeak associations between non-parametric variables and ketamine were found but were not consistent across actigraphy measures. CLINICAL

trial registrationClinicalTrials.gov, NCT00088699.

Indexed as

actigraphycircadianketaminerecurrence quantification analysistreatment-resistant depression

Identifiers

PMID37668277
PMCPMC10804352
OpenAlexW4386439230

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.